Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy

Kidney International

Volumn 50, Issue 3, 1996, Pages 929-936

  Barth, Robert H ^a   DeVincenzo, Nicholas ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; DRUG BLOOD LEVEL; DRUG DOSE; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029785347     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.393     Document Type: Article

References (77)

1. BARCENAS CG, FULLER TJ, ELMS J, COHEN R, WHITE MG: Staphylococcal sepsis in patients on chronic hemodialysis regimens: Intravenous treatment with vancomycin given once weekly. Arch Intern Med 136:1131-1134, 1976
2. KEANE WF, SHAPIRO FL, RAIJ L: Incidence and type of infections occurring in 445 chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 23:41-47, 1977
3. NSOULI KA, LAZARUS M, SCHOENBAUM SC, GOTTLIB MN, LOWRIE EG, SHOCAIR M: Bacteremic infection in hemodialysis. Arch Intern Med 139:1255-125, 1979
4. KESSLER M, HOEN B, MAYEUX D, HESTIN D, FONTENAILLE C: Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 64:95-100, 1993
5. HIGGINS RM: Infections in a renal unit. Q J Med 70:41-51, 1989
6. BARTH RH, DEVINCENZO N: Bacteremia in hospital-based, high-flux hemodialysis: Bacteriology, antibiotic susceptibilities, and relation to vascular access. (abstract) J Am Soc Nephrol 5:432, 1994
7. WALTERS BAJ, MOLINA M, ROSENTHAL AF, DIDOMINIC V, BANDER SJ: Incidence of bacteremia in hemodialysis patients 1993-1994, (abstract) J Am Soc Nephrol 6:567, 1995
8. MOELLERING RC JR, KROGSTAD DJ, GREENBLATT DJ: Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 3(Suppl):S230-S235, 1981
9. MATZKE GR, MCGORY RW, HALSTENSON CE, KEANE WF: Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433-437, 1984
10. BLEVINS RD, HALSTENSON CE, SALEM NG, MATZKE GR: Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 25:603-606, 1984
11. CUNHA BA, QUINTILIANI R, DEGLIN JM, IZARD MW, NIGHTINGALE CH: Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 3(Suppl):S269-S272, 1981
12. BARTH RH, DEVINCENZO N, ZARA AC, BERLYNE GM: Vancomycin pharmacokinetics in high-flux hemodialysis. (abstract) J Am Soc Nephrol 1:348, 1990
13. POLLARD TA, LAMPASONA V, AKKERMAN S, TOM K, HOOKS MA, MULLINS RE, MARONI BJ: Vancomycin redistribution: Dosing recommendations following high-flux hemodialysis. Kidney Int 45:232-237, 1994
14. MATZKE GR, O'CONNELL MB, COLLINS AJ, KESHAVIAH PR: Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther 40:425-430. 1986
15. KELLER F: Vancomycin administration to hemodialysis patients. (abstract) Clin Nephrol 30:173, 1988
16. DE BOCK V, VERBEELEN D, MAES V, SENNESAEL J: Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 4:635-639, 1989
17. LANESE DM, ALFREY PS, MOLITORIS BA: Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 35:1409-1412, 1989
18. BARTH RH, DEVINCENZO N, BERLYNE GM: Revised vancomycin dosing schedule for high-flux hemodialysis. J Am Soc Nephrol 2:314, 1991
19. TORRAS J, CAO C, RIVAS MC, CANO M, FERNANDEZ E, MONTOLIU J: Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 36:35-41, 1991
20. OUALE JM, O'HALLORAN JJ, DEVINCENZO N, BARTH RH: Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 36:1424-1426, 1992
21. DESOI CA, SAHM DF, UMANS JG: Vancomycin elimination during high flux hemodialysis: Kinetic model and comparison of four membranes. Am J Kidney Dis 20:354-360, 1992
22. BÖHLER J, REETZE-BONORDEN P, KELLER E, KRAMER A, SCHOLLMEYER PJ: Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Enr J Clin Pharmacol 42:635-640, 1992
23. ALWAKEEL J, NAJJAR TA, AL-YAMANI MJ, HURAIB S, AL-HAIDER A, ABUTOAISHA H: Comparison of the effects of three haemodialysis membranes on vancomycin disposition. Int Urol Nephrol 26:223-228, 1994
24. KELLER F, HORSTENSMEYER C, LOOBY M, BORNER K, POMMER W, ERDMANN K, GIEHL M: Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters. Int J Artif Organs 17:19-26, 1994
25. TOUCHETTE MA, PATEL RV, ANANDAN JV, DUMLER F, ZAROWITZ BJ: Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 26:469-474, 1995
26. ROTSCHAFER JC, CROSSLEY K, ZASKE DE, MEAD K, SAWCHUK RJ, SOLEM LD: Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 22:391-394, 1982
27. WEST RE: Comment: Monitoring vancomycin therapy. DICP 21:467, 1987
28. MOELLERING RC: Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clin Infect Dis 18:544-546, 1994
29. POHLOD DJ, SARAVOLATZ, LD, SOMERVILLE MM: Comparison of fluorescence polarization immunoassay and bioassay of vancomycin. J Clin Microbiol 20:159-161, 1984
30. EDWARDS DJ, PANCORBO S: Routine monitoring of scum vancomycin concentrations: Waiting for proof of its value. Clin Pharm 6:652-654, 1987
31. FREEMAN CD, QUINTILIANI R, NIGHTINGALE CH: Vancomycin therapeutic drug monitoring: Is it necessary? Ann Pharmacother 27:594-598, 1993
32. CANTÚ TG, YAMANAKA-YUEN NA, LIETMAN PS: Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 18:533-543, 1994
33. LEADER WG, CHANDLER MH, CASTIGLIA M: Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 28:327-342, 1995
34. MACGOWAN A, LOVERING A, WHITE L, REEVES D: Why monitor peak vancomycin concentrations? Lancet 345:645, 1995
35. DUFFULL SB, BEGG EJ: Why monitor peak vancomycin concentrations? Lancet 345:646, 1995
36. COOK FV, FARRAR WE JR: Vancomycin revisited. Ann Intern Med 88:813-818, 1978
37. GREENBERG RN, BENES CA: Time-kill studies with oxacillin. vancomycin, and teicoplanin versus Staphylococcus aureus. J Infect Dis 161:1036-1037, 1990
38. BAILEY EM, RYBAK MJ, KAATZ GW: Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 35:1089-1092, 1991
39. ACKERMAN BH, VANNIER AM, EUDY EB: Analysis of vancomycin time-kill studies with Staphylococcus species by suing a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 36:1766-1769, 1992
40. SAUNDERS NJ: Why monitor peak vancomycin concentrations? Lancet 344:1748-1750, 1994
41. BRUMMET RE: Ototoxicity of vancomycin and analogues. Otolarygol Clin N Am 26:821-828, 1993
42. ACKERMAN BH, VANNIER AM: Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 29:460-461, 1992
43. DE HOOG M, MOUTON JW, VAN DEN ANKER JN: Why monitor peak vancomycin concentrations? Lancet 345:646, 1994
44. DUFFULL SB, BEGG EJ: Why monitor peak vancomycin concentrations? Lancet 345:646, 1994
45. WATANAKUNAKORN C: Mode of action and in vitro activity of vancomycin. J Antimicrob Chemother 14(Suppl D):7-18, 1984
46. TRUBERG JENSEN K, SCHØNHEYDER H, PERS C, FROLUND THOMSEN V: In vitro activity of teicoplanin and vancomycin against Gram-positive bacteria from human clinical and veterinary sources. APMIS 100:543-552, 1992
47. SCHWALBE RS, STAPLETON JT, GILLIGAN PH: Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316:927-931, 1987
48. BIAVASCO F, GIOVANETTI E, MONTANARI MP, LUPIDI R, VARALDO PE: Development of in vitro resistance to glycopeptide antibiotics: Assessment in staphylococci of different species. J Antimicrob Chemother 27:71-79, 1991
49. SHETH NK, FRANSON TR, SOHNLE PG: Influence of bacterial adherence to intravascular catheters on in vitro antibiotic susceptibility. Lancet 2:1266-1268, 1985
50. EVANS RC, HOLMS CJ: Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother 31:889-894, 1987
51. NAYLOR PT, MYRVIK ON, GRISTINA A: Antibiotic resistance of biomaterial-adherent coagulase-negative and coagulase-positive staphylococci. Clin Orthop 261:126-133, 1990
52. CHURAD C, VAUDAUX P, WALDVOGEL FA, LEW DP: Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics. Antimicrob Agents Chemother 37:625-632, 1993
53. WEEB LX, HOLMAN J, DE ARAUJO B, ZACCARO DJ, GORDON ES: Antibiotic resistance in staphylococci adherent to cortical bone. J Orthop Trauma 8:28-33, 1994
54. BAILEY EM, RYKBAK MJ, KAATZ GW: Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 35:1089-1092, 1991
55. KROPEC A, DASCHNER FD: Penetration into tissues of various drugs active against gram-positive bacteria. J Antimicrob Chemother 27(Suppl B):9-15, 1991
56. LAMER C, DE BECO V, SOLER P, CALVAT S, FAGON J-Y, DOMBRET M-C, FARINOTTI R, CHASTRE J, GIBERT C: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37:281-286, 1993
57. WILSON KJ, MADER JT: Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis. Antimicrob Agents Chemother 25:140-141, 1984
58. MORSI GD, NAIRN DK, BERTINO JS, WALSHE JJ: Overestimation of vancomycin concentrationsutilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 9:212-215, 1987
59. WHITE LO, EDWARDS R, HOLT HA, LOVERING AM, FINCH RG, REEVES DS: The in vitro degradation at 37 degrees C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother 22:739-745, 1988
60. ANNE L, HU M, CHAN K, COLIN I, GOTTWALD K: Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: Its detection insera of renally impaired patients. Ther Drug Monit 11:585-591, 1989
61. HORTIN GL, LANDT M, WILHTTE T, SMITH CH: Cross-reactivity of a vancomycin degradation product in three immunoassays of vancomycin. Clin Chem 37:2009, 1991
62. GERACI JE, HEILMAN FR, NICHOLS DR, WELLMAN WE: Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis. Proc Staff Meetings Mayo Clin 33:172-181, 1958
63. SCHAAD UB, NELSON JD, MCCRACKEN GH JR: Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 3(Suppl):S282-S288, 1981
64. HEALY DP, POLK RE, GARSON ML, ROCK DT, COMSTOCK TJ: Comparison of steady-state pharmacokineties of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 31:393-397, 1987
65. GLEW R: Vancomycin, in Infectious Diseases, edited by GORBACH SL, BARTLETT JG, BLACKLOW NR, Philadelphia. WB Saunders. 1992, pp 231-239
66. ZIMMERMANN AE, KATONA BG, PLAISANCE KI: Association of vancomycin serum concentrations with outcomes in patients with grampositive bacteremia. Pharmacotherapy 15:85-91, 1995
67. MULHERN JG, BRADEN GL, O'SHEA MH, MADDEN RL, LIPKOWTTZ GS, GERMAIN MJ: Trough serum vancomyein levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 25:611-615, 1995
68. MOELLERING RC JR: Pharmacokineties of vancomyein. J Antimicrob Chemother 14(Suppl D):43-52, 1984
69. FEKETY R: Vancomycin and teicoplanin. in The Principles and Practice of Infectious Disease (3rd ed), edited hy MANDELL GL, DOUGLAS RG JR, BENNETT JE, New York, Churchill Livingstone, 1989, pp 317-323
70. SHAY DK, MALONEY SA, MONTECALVO M, BANERJEE S, WORMSER GP, ARDUINO MJ, BLAND LA, JARVIS WR: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 172:993-1000, 1995
71. CENTERS FOR DISEASE CONTROL AND PREVENTION: Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 44(RR-12):1-13, 1995
72. SMALL PM, CHAMBERS HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug abusers. Antimicrob Agents Chemother 34:1227-1231, 1990
73. LEVINE DP, FROMM BS, REDDY BR: Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus nureus endocarditis. Ann Intern Med 115:674-680, 1991
74. MORTARA LA, BAYER AS: Staphylococcus aureus bacteremia and endocarditis: New diagnostic and therapeutic concepts. Infect Dis Clin N Am 7:53-68, 1993
75. OWEN WF JR, LEW NL, LIU Y, LOWRIE EG, LAZARUS JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993
76. PARKER T: Hemodialysis adequacy, in Principles and Practice of Dialysis, edited by HENRICH WL, Baltimore, Williams & Wilkins, 1994, pp 63-75
77. BARTH RH: Pros and cons of short, high efficiency, and high flux dialysis, in Replacement of Renal Function by Dialysis (4th ed). edited by WINCHESTER JF, JACOBS C, KJELLSTRAND CM, KOCH KM, Dordrecht, Kluwer, 1996